Clinical Trial Update: A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing JHL1101 to rituximab in previously untreated diffuse large B-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• JHL1101 (JHL1101)
• Rituximab (rituximab)

Snippet

Sponsor: JHL Biotech, Inc. | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: TERMINATED